Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunityBioIBRX +1.82%60 EBITDA Margin % is -380.05% as of Jun. 2026. GuruFocus rates IBRX with a GF Score™ of 60/100 and a GF Value™ of $22.42 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 942 Biotechnology companies, ImmunityBio ranks worse than 72.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ImmunityBio's EBITDA for the
three
months ended in Jun. 2026 was $-194.7 Mil. ImmunityBio's Revenue for the
three
months ended in Jun. 2026 was $51.2 Mil. Therefore, ImmunityBio's EBITDA margin for the quarter that ended in Jun. 2026 was -380.05%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ImmunityBio EBITDA Margin % Related Terms
ImmunityBio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ImmunityBio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IBRX vs RYTM, PCVX, MIRM: EBITDA Margin % Comparison
For the Biotechnology subindustry, ImmunityBio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmunityBio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmunityBio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ImmunityBio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmunityBio (IBRX) has a EBITDA Margin % of -380.05% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ImmunityBio and its competitors. According to the industry distribution chart, ImmunityBio ranks #687 out of 942 companies in the Biotechnology industry, placing it in the top 72.9%.
Is ImmunityBio's EBITDA Margin % too high?
ImmunityBio's current EBITDA Margin % is -380.05%. Based on the distribution chart, ImmunityBio ranks #687 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ImmunityBio has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImmunityBio's EBITDA Margin % compare to RYTM and PCVX?
According to the Biotechnology industry distribution chart, ImmunityBio ranks #687 out of 942 companies for EBITDA Margin %. This places ImmunityBio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ImmunityBio and its competitors. ImmunityBio's current EBITDA Margin % is -380.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmunityBio stock overvalued right now?
Based on GuruFocus' analysis, ImmunityBio (IBRX) is currently considered Possible Value Trap. The stock's GF Value™ is $22.42, compared to a current price of $8.40 — trading 62.6% below its estimated fair value. The current EBITDA Margin % is -380.05%. ImmunityBio's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ImmunityBio (IBRX), the current EBITDA Margin % is -380.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmunityBio (IBRX) Overvalued in 2026?
Based on GuruFocus' analysis, ImmunityBio stock appears to be undervalued.
The current stock price of $8.40 is trading 62.6% below its estimated GF Value™ of $22.42.
GuruFocus considers ImmunityBio to be Possible Value Trap.
Key valuation signals for IBRX:
EBITDA Margin %: -380.05%
GF Value™: $22.42 vs. price of $8.40 (62.6% below fair value)
No single metric tells the full story. See the IBRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
60GF Score
Get the complete analysis for IBRX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBRX has been successfully added to your 
